Nivolumab-related Recurrent Pleural Effusion
Pleural effusions are a rare adverse event with immune checkpoint inhibitors, especially nivolumab. In the CheckMate 057 trial, a phase III trial comparing nivolumab versus docetaxel in advanced squamous NSCLC, 6% of the patients in the nivolumab arm and 3% in the docetaxel arm had a pleural effusion. No pleural effusions were reported as treatment-related serious adverse events.
South Med J. 2020;113(11):600-605. © 2020 Lippincott Williams & Wilkins